Follow-up treatment
Treatment
surgical | oncology

Breast cancer follow-up

Patient Follow-up

Bullet

History eliciting symptoms and physical examination every 3-6 months for 3 years , then 6-12 months for 3 years, then annually with attention paid to long term side-effects (osteoporosis).

Bullet

Ipsilateral and contralateral radiology every year.

Bullet

Not routinely recommended for asymptomatic patients: blood counts; chemistry, chest Xray, bone scan, liver ultrasound, chest scans of chest or abdomen and any tumour marker such as CA 153, CEA are not recommended.

Tumour Markers

Bullet

Serum tumour markers should be used only as a guide to aid treatment decisions and monitor response of not easily measurable disease in the metastatic breast cancer settings and not for screening or diagnosis.

Bullet

The proliferation marker Ki-67 provides important prognostic, particularly for patients with small tumours and no axillary node involvement.

Bullet

Oestrogen and progesterone receptors and their degree of positive are excellent predictors of response in all patients with breast cancer and aid the multi-disciplinary team as to which hormonal therapy should be used.

Over-expression of the Her-2/neu protein is associated with poor prognosis and can be used to select patients for trastuzumab (Herceptin) therapy.